1. Home
  2. TECX vs SENS Comparison

TECX vs SENS Comparison

Compare TECX & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • SENS
  • Stock Information
  • Founded
  • TECX 2019
  • SENS 1996
  • Country
  • TECX United States
  • SENS United States
  • Employees
  • TECX N/A
  • SENS 117
  • Industry
  • TECX
  • SENS Industrial Machinery/Components
  • Sector
  • TECX
  • SENS Industrials
  • Exchange
  • TECX Nasdaq
  • SENS Nasdaq
  • Market Cap
  • TECX 334.4M
  • SENS 472.9M
  • IPO Year
  • TECX 2018
  • SENS N/A
  • Fundamental
  • Price
  • TECX $22.88
  • SENS $0.57
  • Analyst Decision
  • TECX Strong Buy
  • SENS Strong Buy
  • Analyst Count
  • TECX 5
  • SENS 4
  • Target Price
  • TECX $79.00
  • SENS $1.66
  • AVG Volume (30 Days)
  • TECX 249.4K
  • SENS 7.6M
  • Earning Date
  • TECX 08-13-2025
  • SENS 08-06-2025
  • Dividend Yield
  • TECX N/A
  • SENS N/A
  • EPS Growth
  • TECX N/A
  • SENS N/A
  • EPS
  • TECX N/A
  • SENS N/A
  • Revenue
  • TECX N/A
  • SENS $23,682,000.00
  • Revenue This Year
  • TECX N/A
  • SENS $60.14
  • Revenue Next Year
  • TECX N/A
  • SENS $36.55
  • P/E Ratio
  • TECX N/A
  • SENS N/A
  • Revenue Growth
  • TECX N/A
  • SENS 1.64
  • 52 Week Low
  • TECX $13.70
  • SENS $0.25
  • 52 Week High
  • TECX $61.07
  • SENS $1.40
  • Technical
  • Relative Strength Index (RSI)
  • TECX 53.91
  • SENS 59.13
  • Support Level
  • TECX $21.41
  • SENS $0.57
  • Resistance Level
  • TECX $23.87
  • SENS $0.61
  • Average True Range (ATR)
  • TECX 1.57
  • SENS 0.03
  • MACD
  • TECX 0.08
  • SENS 0.01
  • Stochastic Oscillator
  • TECX 54.84
  • SENS 52.87

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Share on Social Networks: